AstraZeneca (AZN) Q1 2026 earnings review
Oncology Surges, but CVRM Patent Cliffs Loom Large
AstraZeneca delivered a robust Q1 2026, with Total Revenue accelerating 13% YoY to $15.3 billion. The growth was heavily polarized: the Oncology and Rare Disease segments surged, while the Cardiovascular, Renal & Metabolism (CVRM) segment stagnated under the weight of generic competition and China's Volume-Based Procurement (VBP) pricing. Despite these headwinds, Core EPS grew 5% to $2.58. The company is aggressively investing in its pipeline to bridge the gap, evidenced by R&D spending taking 23% of revenue and CapEx guided to jump ~33% this year. Management reiterated FY26 guidance for mid-to-high single-digit revenue growth, signaling confidence that their 'catalyst-rich' pipeline will outrun impending patent cliffs.
🐂 Bull Case
With 4 high-value Phase III readouts already positive in Q1 (including tozorakimab and efzimfotase alfa) and 20 major readouts expected in 2026, AstraZeneca's pipeline represents over $10 billion in risk-adjusted peak-year revenue potential.
The Oncology segment grew an impressive 20% to $6.8 billion, driven by massive demand for Imfinzi (+34%) and Enhertu (+40%). AstraZeneca successfully continues to push these blockbusters into earlier lines of therapy.
🐻 Bear Case
The CVRM segment is reversing, dropping 6% at Constant Exchange Rates (CER). Farxiga faces a brutal loss of exclusivity (LOE) in the US in April 2026 and immediate VBP pricing pressures in China.
Core Gross Margin declined slightly to 83% from 84%, while CapEx is guided to increase by ~33% in FY26 to expand manufacturing. This heavy investment cycle will place a near-term drag on free cash flow.
⚖️ Verdict: 🟢
Bullish. While the Farxiga cliff and China VBP are real, quantified threats, the company's aggressive and successful pipeline execution—particularly in Oncology and Respiratory—provides a highly credible bridge to its $80 billion 2030 revenue ambition.
Key Themes
Oncology Engine Accelerating
Oncology remains AstraZeneca's most critical growth driver, accelerating 20% YoY to $6.8 billion. Imfinzi (+34%) and Enhertu (+40%) were the standout performers, benefiting from new launches in GI and GU cancers and early breast cancer settings. The data presented at ASCO, including the EMERALD-3 trial showing Imfinzi moving earlier into locoregional HCC, secures a long-term growth trajectory for the franchise.
CVRM Segment Reversing Under Generic Assault
The CVRM segment was the glaring weak spot, with reported revenue flat (+0%) and down 6% at CER. The root cause is the simultaneous hit of generic competition for Brilinta (-65%) and Farxiga VBP implementation in China. With Farxiga's US loss of exclusivity looming in April 2026, this segment will remain under intense pressure, requiring the Respiratory & Immunology portfolio to pick up the slack.
Respiratory & Immunology Picking Up the Baton
R&I is accelerating beautifully to offset CVRM losses, growing 15% YoY to $2.3 billion. Fasenra (+15%), Breztri (+18%), and Tezspire (+40%) are taking significant market share. Notably, the positive Phase III readouts for the IL-33 biologic 'tozorakimab' in COPD (OBERON, TITANIA, MIRANDA trials) positions AstraZeneca to capture a massive $3-5 billion peak-year revenue opportunity in a market where less than 5% of eligible patients are currently on a biologic.
Rare Disease Conversion Strategy Succeeding
The Rare Disease segment proved highly stable, growing 19% YoY to $2.4 billion. The strategy to convert patients from the older Soliris to the newer Ultomiris is working perfectly. Ultomiris grew 21% to $1.27 billion, more than offsetting the 12% decline in Soliris, which is facing biosimilar competition. Additionally, Strensiq surged 47% on strong global demand.
Spiking Capital Expenditure and R&D Costs
AstraZeneca's commitment to its $80 billion 2030 ambition is expensive. R&D expenses rose 11% to $3.49 billion (23% of revenue) to fund over 100 Phase III trials. Furthermore, CapEx jumped to $645 million in Q1 2026 (up from $493 million in Q1 2025). Management guided that full-year CapEx will increase by roughly one-third versus FY25 to support manufacturing expansions in the US, China, and Singapore, which will temporarily compress free cash flow generation.
Strategic Shift into Weight Management
AstraZeneca is aggressively positioning itself for the post-2030 landscape by entering the highly lucrative, yet intensely competitive, obesity market. The company closed a $1.2 billion upfront strategic collaboration with CSPC to advance next-generation therapies, and management expressed supreme confidence in their oral GLP-1, elecoglipron, advancing to Phase III based on a highly competitive monotherapy profile.
Other KPIs
Accelerating. Up 11% YoY (12% CER), driven by robust top-line growth and disciplined SG&A spending, which grew only 10% (below the 13% revenue growth). This resulted in Core Operating Margin improving slightly to 35% at CER.
Decelerating. Down from $3,713 million in Q1 2025. The $354 million decrease was primarily driven by negative movements in working capital and short-term provisions, alongside foreign exchange fluctuations, despite the increase in operating profit.
Stable. Down 1 percentage point actual, but up 1 percentage point at CER. Margin profile is being slightly diluted by the success of partnered drugs (like Enhertu and Lynparza) where AstraZeneca pays a share of gross profits to collaborators like Daiichi Sankyo and Merck.
Guidance
Stable. Reconfirmed at CER. Assuming a midpoint of ~7.5%, this shows management's confidence that the strong momentum in Oncology and R&I will more than absorb the imminent Farxiga patent cliff in the US and VBP impacts in China.
Stable. Reconfirmed at CER. This implies continued operating leverage as the company scales its newer blockbuster medications, effectively managing the heavy R&D burden required for its massive Phase III pipeline.
Stable. The Q1 2026 core tax rate landed right in the middle of this range at 21%. This represents a normalization from the prior year's unusually low rate that benefited from tax authority settlements.
Key Questions
Farxiga US LOE Bridging Strategy
With the US loss of exclusivity for Farxiga hitting in April 2026, can the aggressive ramp in Respiratory & Immunology fully offset this massive high-margin revenue crater, or should we expect temporary margin compression in H2 2026?
Obesity Market Differentiation
Given the entrenched duopoly in the obesity and weight management market, what specific clinical data points give you confidence that elecoglipron can win as a monotherapy, rather than just serving as a combination agent?
CapEx Cycle Normalization
Capital expenditure is guided to increase by a third this year to support global manufacturing expansion. Is 2026 the peak of this investment cycle, and when can investors expect CapEx as a percentage of revenue to normalize, freeing up more cash flow for buybacks?
Imfinzi in Bladder Cancer
With competitors like Merck's KEYTRUDA showing aggressive moves in the bladder cancer space, how confident are you in Imfinzi's ability to maintain the momentum established by the NIAGARA regimen?